Biosimilar Epoetin Zeta in Oncology and Haematology: Development and Experience following 6 Years of Use

Acta Haematologica

Volumn 135, Issue 1, 2015, Pages 44-52

  Michallet, Mauricette ^a   Losem, Christoph ^b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b Praxis Hämatologie und Onkologie Neuss   (Germany)

Author keywords

Biosimilars; Chemotherapy induced anaemia; Epoetin alfa; Epoetin zeta; Erythropoietin; Haematology; Oncology

Indexed keywords

BIOSIMILAR AGENT; RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANEMIA; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG LABELING; DRUG MANUFACTURE; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG USE; EXPERIENCE; HEMATOLOGIST; HEMATOLOGY; HUMAN; MULTICENTER STUDY (TOPIC); ONCOLOGIST; ONCOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL ANEMIA; REVIEW; CHEMICALLY INDUCED; NEOPLASMS; PATHOLOGY;

ANEMIA; BIOSIMILAR PHARMACEUTICALS; ERYTHROPOIETIN; HUMANS; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 84942693123     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000438976     Document Type: Review

References (36)

1. Ludwig H, van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.
2. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634.
3. Cella D, Kallich J, McDermott A, Xu X: The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004; 15: 979-986.
4. Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N, Jenkinson C, Grey-Amante P, Doll H, Wild D: The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002; 86: 1243-1249.
5. Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001; 91: 2214-2221.
6. Aapro MS, Link H: September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008; 13(suppl 3):33-36.
7. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28: 4996-5010.
8. European Generic Medicines Association: Biosimilars Handbook, ed 2. Brussels, European Generic Medicines Association, 2011.
9. European Medicines Agency: Guideline on similar biological medicinal products. 2005. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003517.pdf (accessed December 2014).
10. World Health Organization: Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009 http://www.who.int/biologicals/ areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf (accessed December 2014).
11. Macdougall IC: Biosimilar epoetins. Nephrol Dial Transplant 2009; 24: 1698-1699.
12. Aapro M, Cornes P, Sun D, Abraham I: Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol 2012; 4: 95-105.
13. Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H: Quality of original and biosimilar epoetin products. Pharm Res 2011; 28: 386-393.
14. Pharmaceutical Research and Manufacturers of America: Biopharmaceutical research and development: The process behind new medicines. 2007. http://www.phrma.org/sites/default/ files/pdf/rd-brochure-022307.pdf (accessed September 2015).
15. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R: Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29: 310-312.
16. European Medicines Agency: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2013. http://www.ema.europa.eu/docs/ en-GB/document-library/Scientific-guideline/ 2013/06/WC500144124.pdf (accessed December 2014).
17. European Medicines Agency: Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (revision). 2010. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2010/04/WC500089474.pdf (accessed December 2014).
18. European Medicines Agency: Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor. 2006. http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003955.pdf (accessed December 2014).
19. European Medicines Agency: Guidance on similar medicinal products containing somatropin. 2006. http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003956.pdf (accessed December 2014).
20. Mellstedt H, Niederwieser D, Ludwig H: The challenge of biosimilars. Ann Oncol 2008; 19: 411-419.
21. Kirkov V, Dimitrova V, Siebert-Weigel M, Wolf-Pflugmann M, Koytchev R, Richter W, Bronn A, Arsova S, Kromminga A: Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st communication: A monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers. Arzneimittelforschung 2008; 58: 215-219.
22. Kirkov V, Dimitrova V, Siebert-Weigel M, Wolf-Pflugmann M, Koytchev R, Richter W, Bronn A, Arsova S, Kromminga A: Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd communication: A monocentric, double-blind, randomized, single dose, three-period crossover trial in healthy volunteers. Arzneimittelforschung 2008; 58: 220-224.
23. Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R, Epoetin Zeta Study Group: Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia. Curr Med Res Opin 2008; 24: 1407-1415.
24. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group: Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin 2008; 24: 625-637.
25. Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A, Epoetin Zeta Study Group: Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 2010; 27: 105-117.
26. Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A: Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther 2008; 25: 1215-1228.
27. Tzekova V, Mihaylov G, Elezovic I, Koytchev R: Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia. Curr Med Res Opin 2009; 25: 1689-1697.
28. Dammacco F, Castoldi G, Rödjer S: Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113: 172-179.
29. Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe LM, Labourey JL, Lepille D, Maloisel F, Mouysset JL, Nahon S, Narciso B, Nouyrigat P, Radji R, Sakek N, Albrand H, ORHEO study group: Biosimilars in the management of anaemia secondary to chemotherapy in haematology and oncology: results of the ORHEO observational study. BMC Cancer 2014; 14: 503.
30. ClinicalTrials.gov: Biosimilar Retacrit TM (epo etin zeta) in the treatment of chemotherapy-induced symptomatic anaemia in haematology and oncology. 2014. www.clinicaltrials. gov/ct2/show/NCT01626547?term=ery thropoetin+zeta&rank=2 (accessed December 2014).
31. Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I: Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. Cancer 2013; 119: 107-114.
32. Niederwieser D, Schmitz S: Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 2011; 86: 277-288.
33. Minghetti P, Rocco P, Del Vecchio L, Locatelli F: Biosimilars and regulatory authorities. Nephron Clin Pract 2011; 117:c1-c7.
34. Covic A, Cannata-Andia J, Cancarini G, Coppo R, Frazão JM, Goldsmith D, Ronco P, Spasovski GB, Stenvinkel P, Utas C, Wiecek A, Zoccali C, London G: Biosimilars and biopharmaceuticals: what the nephrologists need to know-A position paper by the ERA-EDTA Council. Nephrol Dial Transplant 2008; 23: 3731-3737.
35. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8-32.
36. Ebbers HC, Muenzberg M, Schellekens H: The safety of switching between therapeutic proteins. Expert Opin Biol Ther 2012; 12: 1473-1485.